Speakers

Expand/Collapse

Andrew Wylie
Senior Vice President & Head of Oncology
KSQ Therapeutics

Day Two

Thursday 13th December 2018

12:00 pm | Exploring KSQ-4279, a First in Class USP1 Inhibitor for the Treatment of Tumors with Defects in DNA Damage Repair

Nathalie Agar
Director of Surgical Molecular Imaging, Laboratory & Department of Neurosurgery
Brigham & Women’s Hospital Department of Cancer Biology Dana-Farber Cancer Institute

Day One

Thursday 13th December 2018

4:00 pm | Panel Discussion: Towards Bridging the Gap with the Clinic

3:00 pm | Exploring DDR-Specific Companion Diagnostics for Understanding Target Function, Activity, Trial Design & Clinical Response

Timothy Yap
Associate Professor, Investigational Cancer Therapeutics
MD Anderson Cancer Center

Day One

Thursday 13th December 2018

12:30 pm | Panel Discussion: A Comparison; The Challenges & Learnings of Developing ATR inhibitors – What Clinical Space Will They Occupy?

Day Two

Thursday 13th December 2018

4:30 pm | Targeting ATR in the Clinic: Novel Agents and Rational Combinations

Geoffrey Shapiro
Professor, Medicine, Harvard Medical School, Director of Early Drug Development Center
Dana-Farber Cancer Institute

Day One

Thursday 13th December 2018

4:00 pm | Panel Discussion: Towards Bridging the Gap with the Clinic

Caroline Ben
Chief Scientific Officer & Co- Founder
LoQus23 Therapeutics

Ioannis Gounaris
Senior Medical Director Cluster Lead DNA Damage Response (DDR) Inhibitors, Global Clinical Development Oncology Group II
Merck KGaA

Day Two

Thursday 13th December 2018

8:30 am | ATR Inhibitor-Based Combination Treatments in the Clinic: Biomarkers for Patient Selection

8:00 am | Breakfast Panel: Assessing the Situation: Improving Biomarker Characterization, Aiding Predictive Drug Development & Advancements in Addressing Patient Heterogeneity

Frank Zenke
Global Head DNA Damage Response Research
Merck KGaA

Day One

Thursday 13th December 2018

12:30 pm | Panel Discussion: A Comparison; The Challenges & Learnings of Developing ATR inhibitors – What Clinical Space Will They Occupy?

10:00 am | Preclinical & Clinical Exploration of ATR Inhibitors

John Pascal
Professor of Biochemistry & Molecular Medicine
University of Montreal

Oren Gilad
Chief Executive Officer
Atrin Pharmaceuticals

Day One

Thursday 13th December 2018

10:30 am | Progress in ATR & WEE1 Inhibitors: As Single Agents & Synergy in Combination Therapy

Debanu Das
Chief Executive Officer
XPose Therapeutics

Day One

Thursday 13th December 2018

2:30 pm | HTS & the Best Assays for Compound Optimization & Synthetic Lethal Screening in DDR Quick SAR by X-ray Poses

Zineb Mounir
Director, Biology & Translational Science
IDEAYA Biosciences

Day Two

Thursday 13th December 2018

11:30 am | Developing a PARG Inhibitor

Sui Xiong Cai
Executive Vice President & Chief Technology Officer
IMPACT Therapeutics

Day One

Thursday 13th December 2018

12:30 pm | Panel Discussion: A Comparison; The Challenges & Learnings of Developing ATR inhibitors – What Clinical Space Will They Occupy?

Mark O’Connor
Chief Scientist & Senior Principal Scientist
AstraZeneca

Day One

Thursday 13th December 2018

12:00 pm | Targeting Replication Stress in Cancers with Adavosertib, the First in Class WEE1 Inhibitor

9:30 am | Panel Discussion: PARPi’s: The Whole Story? PARP & DDR Biomarkers, Targets & Hope in Indications Outside of Breast & Ovarian

Day Two

Thursday 13th December 2018

5:00 pm | Closing Panel Discussion: Future Directions for DDRi

Ranjit Bindra
Professor, Departments of Therapeutic Radiology & Pathology
Yale School of Medicine

Day One

Thursday 13th December 2018

4:00 pm | Panel Discussion: Towards Bridging the Gap with the Clinic

Day Two

Thursday 13th December 2018

5:00 pm | Closing Panel Discussion: Future Directions for DDRi

Peter Huang
Senior Vice President Discovery
Zentalis Pharmaceuticals

Day One

Thursday 13th December 2018

11:30 am | Discovery & Progress of ZN-c3, a Highly Potent & Selective WEE1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer

Elisabetta Leo
Principal Scientist - Associate Director
AstraZeneca

Day One

Thursday 13th December 2018

9:30 am | Panel Discussion: PARPi’s: The Whole Story? PARP & DDR Biomarkers, Targets & Hope in Indications Outside of Breast & Ovarian

8:30 am | Progress in PARP1 Selective Inhibitors: AZD5305

Kent Mouw
Assistant Professor of Radiation Oncology
Dana-Farber Cancer Institute

Day Two

Thursday 13th December 2018

12:30 pm | Emerging Roles of the ATR/CHK1 Axis in Nucleotide Excision Repair

Nicola Curtin
Experimental Therapeutics Professor
Newcastle University

Day Two

Thursday 13th December 2018

2:30 pm | Durability of PARP Inhibition: Implications for Dose & Schedule as Single Agent & Combination Therapy

Helen Robinson
Vice President of Biology
Artios Pharma

Day One

Thursday 13th December 2018

4:30 pm | Exploring Polθ as a New DDR Target

Alan D’Andrea
Director: Center for DNA Damage and Repair, Director
Susan F. Smith Center for Women’s Cancers (SFSCWC) Professor Harvard Medical School Dana-Farber Cancer Institute

Day One

Thursday 13th December 2018

4:00 pm | Panel Discussion: Towards Bridging the Gap with the Clinic

2:00 pm | Understanding the Promising Methods for Exploring Novel Biomarkers

Kirk Tanner
Chief Scientific Officer
National Brain Tumor Society

Day One

Thursday 13th December 2018

9:30 am | Panel Discussion: PARPi’s: The Whole Story? PARP & DDR Biomarkers, Targets & Hope in Indications Outside of Breast & Ovarian

Day Two

Thursday 13th December 2018

3:00 pm | DDRi R&D in CNS Tumors: Landscape & Opportunities

Tatjana Stankovic
Institute of Cancer and Genomic Sciences
University of Birmingham

Day Two

Thursday 13th December 2018

4:00 pm | Understanding Connections Between Immune Response & DNA Damage Defects in Chronic Lymphocytic Leukaemia ( CLL) as a Disease Model

Katie Pawelczak
VP of Research
NERx Biosciences

Day Two

Thursday 13th December 2018

11:00 am | Targeting Protein-DNA Interactions in the DNA Damage Response: Lead Identification & Optimization for Novel Inhibitors of Replication Protein A (RPA) & Ku

Sotirios Sotiriou
Head of Biology & Co-Founder
FoRx Therapeutics

Day Two

Thursday 13th December 2018

8:00 am | Breakfast Panel: Assessing the Situation: Improving Biomarker Characterization, Aiding Predictive Drug Development & Advancements in Addressing Patient Heterogeneity

John Pollard
Vice President & Global Head of Translational Medicine & Oncology
Bayer

Day One

Thursday 13th December 2018

12:30 pm | Panel Discussion: A Comparison; The Challenges & Learnings of Developing ATR inhibitors – What Clinical Space Will They Occupy?

Day Two

Thursday 13th December 2018

5:00 pm | Closing Panel Discussion: Future Directions for DDRi

Eytan Ruppin
Chief - Cancer Data Science Lab
National Cancer Institute

Day Two

Thursday 13th December 2018

10:00 am | Synthetic Lethality-Mediated Precision Oncology

Wael Jdey
Lead Scientist
Onxeo

Day One

Thursday 13th December 2018

9:30 am | Panel Discussion: PARPi’s: The Whole Story? PARP & DDR Biomarkers, Targets & Hope in Indications Outside of Breast & Ovarian

Day Two

Thursday 13th December 2018

9:30 am | Drug-driven HRD: From Bench to Bedside & Back: Discovering Novel Biomarkers for PARP

8:00 am | Breakfast Panel: Assessing the Situation: Improving Biomarker Characterization, Aiding Predictive Drug Development & Advancements in Addressing Patient Heterogeneity

Daniel Speidel
Managing Director & Co-Founder
Breakpoint Therapeutics

Day Two

Thursday 13th December 2018

5:00 pm | Closing Panel Discussion: Future Directions for DDRi

Graeme Smith
Chief Scientific Officer
Artios Pharmaceuticals

Day Two

Thursday 13th December 2018

7:50 am | Chair’s Opening Remarks

Michael Zinda
Chief Scientific Officer, Executive Vice President, Head of Research & Development
Repare Therapeutics

Day Two

Thursday 13th December 2018

1:30 pm | Progress in PKMYT1 Inhibition: RP-6306

Arne Nedergaard
Kousholt Postdoctoral Researcher
Jos Jonkers Group, Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute

Asli Muvaffak
Associate Director - Scientific, Oncology, Synthetic Lethality & Research Unit
GSK

Laure Escoubet
Vice President, Discovery Biology
Zentalis Pharmaceuticals

Day One

Thursday 13th December 2018

8:20 am | Chair’s Opening Remarks

Asima Mukhopadhyay
Gynaecological Oncologist & Clinician Scientist,
Chittaranjan National Cancer Institute India & Newcastle University

Day Two

Thursday 13th December 2018

2:30 pm | Durability of PARP Inhibition: Implications for Dose & Schedule as Single Agent & Combination Therapy

Jennifer Molina
Principal Scientist
Ribon Therapeutics

Day One

Thursday 13th December 2018

9:00 am | Inhibition of PARP7 by RBN-2397 Activates the Type I Interferon Response in Tumors Leading to Robust Antitumor Activity